Skip to main content
. 2021 Apr 10;22(8):3916. doi: 10.3390/ijms22083916

Figure 6.

Figure 6

The Cis+Nira therapy is effective against three-dimensional (3D) cultures of Twist-knockdown CisR OC cells. (A) The schematic diagram showing the experimental protocol for the formation 3D spheroid and treatment plan of DMSO, Cis, and Nira. (B) The images representing 3D spheroids formation of siNC and siTwist transfected cells at 0, 1, 3 and 5 days on OV90-CisR and SKOV3-CisR (Magnification, 10×, scale bar 100 µm). The cells were cultured in absence or presence of Cis (18 µm, OV90—CisR; 21 µm, SKOV3-CisR) and Nira (17.5 µm, OV90—CisR; 15 µm, SKOV3-CisR) for 120 h. (Magnification, 10×, scale bar 100 µm) (C) Relative cell viability of siNC and siTwist transfected 3D culture cells administered with DMSO, Cis, Nira, and Cis+Nira in OV90-CisR (18 µm of Cis and 17.5 µm of Nira) and SKOV3-CisR (21 µm of Cis and 15 µm of Nira) OC cells. CisR: cisplatin-resistant; siRNA: small interfering RNA; siNC: non-targeting negative control, siRNA; siTwist: Twist siRNA; DMSO: dimethyl sulfoxide, Cis: cisplatin; Nira: niraparib. Values were represented as mean ± SD. # p < 0.05, compared with siNC group; * p < 0.05, compared with the siTwist (DMSO) group.